التفاصيل البيبلوغرافية
العنوان:
Non-alcoholic fatty liver disease: A patient guideline
المؤلفون:
Shira Zelber-Sagi , Rebecca Dorner , Giulio Marchesini , Marko Korenjak , Christos Lionis , Jeffrey V. Lazarus , Sven Francque , Achim Kautz , Luca Busetto , José Willemse , G. Koek , Dror Dicker , Kate Hallsworth , Shlomo Vinker , Gema Frühbeck , Euan Woodward , Mehmet Ungan , Juan M. Mendive , Martine Walmsley
المساهمون:
Francque, Sven M, Marchesini, Giulio, Kautz, Achim, Walmsley, Martine, Dorner, Rebecca, Lazarus, Jeffrey V, Zelber-Sagi, Shira, Hallsworth, Kate, Busetto, Luca, Frühbeck, Gema, Dicker, Dror, Woodward, Euan, Korenjak, Marko, Willemse, José, Koek, Gerardus H, Vinker, Shlomo, Ungan, Mehmet, Mendive, Juan M, Lionis, Christos, Interne Geneeskunde, MUMC+: MA Maag Darm Lever (9), RS: NUTRIM - R2 - Liver and digestive health
المصدر:
JHEP Reports
سنة النشر:
2021
مصطلحات موضوعية:
NASH, non-alcoholic steatohepatiti , Y GASTRIC BYPASS , Disease , RC799-869 , PLACEBO-CONTROLLED TRIAL , LIFE-STYLE MODIFICATION , cardiovascular disease , LDL, low-density lipoprotein , HEPATOCELLULAR-CARCINOMA , non-invasive test , T2D , GLP-1 RAs, glucagon-like receptor 1 agonists , European Association for the Study of Obesity , HCC , Gastroenterology , NASH , specific , Diseases of the digestive system. Gastroenterology , CAP , controlled attenuation parameter , CT, computed tomography , FXR , ASH, alcoholic steatohepatitis , GP , non-alcoholic steatohepatitis , GLP-1 RAs, glucagon-like receptor 1 agonist , LDL, low-density lipoproteins , medicine.medical_specialty , HDL , achievable , NASH, non-alcoholic steatohepatitis , T2D, type 2 diabetes , high-density lipoprotein , CVD, cardiovascular disease , LDL , Patient Guideline , Quality of life (healthcare) , FXR, farnesoid X receptor , NAFLD , low-density lipoproteins , GP, general practitioner , NAFL, non-alcoholic fatty liver , FIB-4, fibrosis-4 index , Intensive care medicine , computed tomography , Guideline , medicine.disease , T1D, type 1 diabete , digestive system diseases , NIT , Human medicine , farnesoid X receptor , type 1 diabetes , BMI, body mass index , EASL, European Association for the Study of the Liver , Placebo-controlled study , Chronic liver disease , GLP-1 RAs , QUALITY-OF-LIFE , alcoholic steatohepatitis , European Association for the Study of Diabetes , EASD, European Association for the Study of Diabetes , Immunology and Allergy , magnetic resonance imaging , NASH Clinical Research Network , ALD, alcohol-related or alcoholic liver disease , Disease management (health) , glucagon-like receptor 1 agonists , EASO, European Association for the Study of Obesity , NASH CRN, NASH Clinical Research Network , ASH, alcoholic steatohepatiti , Fatty liver , timely , hepatocellular carcinoma , CVD , magnetic resonance elastography , MRE , NAFL , FIB-4 , non-alcoholic fatty liver , type 2 diabetes , T1D, type 1 diabetes , CAP, controlled attenuation parameter , CT , European Association for the Study of the Liver , MRI , fibrosis-4 index , NAFLD, non-alcoholic fatty liver disease , EASD , HDL, high-density lipoprotein , UNITED-STATES , ASH , body mass index , EASL , measurable , BMI , NIT, non-invasive test , Internal Medicine , medicine , NASH CRN , HEPATIC STEATOSIS , HCC, hepatocellular carcinoma , MRE, magnetic resonance elastography , MRI, magnetic resonance imaging , SMART, specific, measurable, achievable, relevant, timely , Disease burden , BARIATRIC SURGERY , Hepatology , SMART , business.industry , SERUM ALANINE AMINOTRANSFERASE , non-alcoholic fatty liver disease , PHYSICAL-ACTIVITY , alcohol-related or alcoholic liver disease , EASD, European Association for the Study of Diabete , EASO , ALD , general practitioner , relevant , T1D , business
الوصف:
This patient guideline is intended for all patients at risk of or living with non-alcoholic fatty liver disease (NAFLD). NAFLD is the most frequent chronic liver disease worldwide and comes with a high disease burden. Yet, there is a lot of unawareness. Furthermore, many aspects of the disease are still to be unravelled, which has an important impact on the information that is given (or not) to patients. Its management requires a close interaction between patients and their many healthcare providers. It is important for patients to develop a full understanding of NAFLD in order to enable them to take an active role in their disease management. This guide summarises the current knowledge relevant to NAFLD and its management. It has been developed by patients, patient representatives, clinicians and scientists and is based on current scientific recommendations, intended to support patients in making informed decisions. (C) 2021 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL).
وصف الملف:
ELETTRONICO
تدمد:
2589-5559
الوصول الحر:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cc5e84bfe19b52d5e0324b299615b0e1Test https://pubmed.ncbi.nlm.nih.gov/34693236Test
حقوق:
OPEN
رقم الانضمام:
edsair.doi.dedup.....cc5e84bfe19b52d5e0324b299615b0e1
قاعدة البيانات:
OpenAIRE
